Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.41 |
| ▸ | SLC16A1 | P53985 | 3/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17316500 | 0.86 | CACNA1H (0.46) | CACNA1HRIPK1RIPK3 | |
| SCHEMBL6739781 | 0.82 | KMO (0.56) | KMOCACNA1HMCHR1PLA2G4AHTR2A | |
| SCHEMBL6743315 | 0.80 | KMO (0.42) | KMOCACNA1HRIPK1RIPK3 | |
| SCHEMBL17316718 | 0.78 | CACNA1H (0.50) | CACNA1HHTR2A | |
| SCHEMBL19159359 | 0.75 | HTR2A (0.45) | KMOCACNA1HPLA2G4AHTR2AHTR2C | |
| SCHEMBL28341759 | 0.75 | MTNR1A (0.43) | CACNA1HSLC16A3SLC16A1RIPK1RIPK3 | |
| SCHEMBL22506942 | 0.73 | MTNR1A (0.48) | RIPK1RIPK3 | |
| SCHEMBL18691035 | 0.72 | CACNA1H (0.53) | KMOCACNA1HPLA2G4A | |
| SCHEMBL23055588 | 0.72 | KMO (0.55) | KMOPLA2G4AHTR2AHTR2CHTR2B | |
| SCHEMBL24782853 | 0.72 | KMO (0.45) | KMOPLA2G4AHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | KMO 453/4885CACNA1H 239/4885SLC16A3 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.